Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fleeting popularity

Fleeting popularity

When the CFOs attending the Association of Bioscience Financial Officers annual meeting in San Francisco assembled to hear representatives of the national media last week, the message was - in a word - a bummer. The correspondents from Business Week, The Wall Street Journal and The New York Times all related versions of the same message: Vanishing space for biotech stories, fewer reporters covering the industry and dwindling interest on the part of their editors.

BioCentury, represented by its publisher,

Read the full 810 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers